(Q51355700)

English

Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.

scientific article published on 8 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

type 2 diabetes

0 references

author name string

Hong Zhang

1

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

Xiangcheng Zhang

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

Changjun Hu

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

Weiping Lu

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

publication date

8 June 2012

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

Kidney and Blood Pressure Research

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

35

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

6

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

483-488

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

Prevalence of diabetes among men and women in China

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Management of diabetes mellitus in clinical practice

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Obesity, diabetes, and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

1 reference

https://api.crossref.org/works/10.1159%2F000337929

21 January 2018

Identifiers

10.1159/000337929

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22687869

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51355700&oldid=1234742974"